Why the study?
Does chlorthalidone improve cardiovascular outcomes compared to hydrochlorothiazide in first-time users for hypertension treatment?
Does chlorthalidone improve cardiovascular outcomes compared to hydrochlorothiazide in first-time users for hypertension treatment?
In first-time users treated for hypertension, chlorthalidone does not offer cardiovascular benefits over hydrochlorothiazide and carries a higher risk of renal and electrolyte adverse events.
Chlorthalidone showed no cardiovascular benefit over hydrochlorothiazide with higher renal risks; leaves open confirmation in randomized hypertension trials.
This study found that chlorthalidone use was not associated with significant cardiovascular benefits when compared with hydrochlorothiazide, while its use was associated with greater risk of renal and electrolyte abnormalities. These findings do not support current recommendations to prefer chlorthalidone vs hydrochlorothiazide for hypertension treatment in first-time users was found. We used advanced methods, sensitivity analyses, and diagnostics, but given the possibility of residual confounding and the limited length of observation periods, further study is warranted.
No takes yet. Share an insight, caveat, or question.
Hripcsak et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: